MUC16 and non-small cell lung carcinoma: Next, the specific binding of ch5E6 to murine Muc16 in KPC cell lines, tissues, and tumoroids derived from clinically relevant KPC model of PDAC proved particularly interesting, as it underscores the importance of exploring mAb therapeutic utility in clinically relevant syngeneic mouse models of PDAC and NSCLC in the near future.